创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

靶向成纤维细胞活化蛋白的放射性药物在肿瘤诊疗中的研究进展

Research Progress of Fibroblast Activation Protein-Targeted Radiopharmaceuticals in Tumor Diagnosis and Treatment

  • 摘要: 成纤维细胞活化蛋白(fibroblast activation protein,FAP)因其在肿瘤相关成纤维细胞(cancer-associated fibroblast,CAF)中的特异性高表达,成为肿瘤治疗领域备受关注的潜在靶点。近年来,靶向FAP的放射性药物因其特异性和潜在的治疗效果而受到广泛关注。这些靶向药物在肿瘤诊断和治疗中的应用潜力巨大,尤其是在实体肿瘤的精准诊疗中表现出卓越的性能。研究表明,这些药物能够特异性地递送放射性核素至肿瘤微环境中的CAF,从而实现对肿瘤的精准治疗。通过总结靶向FAP的放射性药物类型及其作用机制,分析其在肿瘤诊疗中的研究进展,旨在为未来靶向FAP的放射性药物研发提供参考。

     

    Abstract: Fibroblast activation protein ( FAP ) has become a potential target in the field of tumor therapy in recent years due to its specific high expression in cancer-associated fibroblast(CAF). In recent years, radiopharmaceuticals targeting FAP have received extensive attention due to their specificity and potential therapeutic effects. These targeted drugs have great potential in the diagnosis and treatment of tumors, especially in the precise diagnosis and treatment of solid tumors. Studies have shown that these drugs can specifically deliver radionuclides to CAF in the tumor microenvironment, thereby achieving precise treatment of tumors. By summarizing the types of radiopharmaceuticals targeting FAP and their mechanism of action, and analyzing the research progress of FAP in tumor diagnosis and treatment, this paper aims to provide some reference for future development of FAP-targeted radiopharmaceuticals.

     

/

返回文章
返回